You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
11.30.15
Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan
11.30.15
Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation
11.04.15
Ironwood Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference
11.03.15
Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update
11.03.15
Ironwood Pharmaceuticals Initiates Clinical Studies of Soluble Guanylate Cyclase Stimulators IW-1973 and IW-1701
11.02.15
Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation
10.27.15
Allergan Acquires Rights To Ironwood's CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries
10.19.15
Ironwood Highlights Refractory GERD and Constipation Research at the American College of Gastroenterology 2015 Annual Scientific Meeting
10.14.15
Ironwood Pharmaceuticals to Host Third Quarter 2015 Investor Update Call
10.13.15
Ironwood Reports Positive Top-Line Results from Phase III Trial of 72 mcg Linaclotide in Adults with Chronic Idiopathic Constipation
09.10.15
Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
08.05.15
Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update
08.05.15
Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with Diarrhea (IBS-D) in the U.S.
07.22.15
Ironwood Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973
07.15.15
Ironwood Pharmaceuticals to Host Second Quarter 2015 Investor Update Call
07.08.15
AstraZeneca and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Designed to Support Linaclotide Approval in China
06.10.15
Ironwood Pharmaceuticals Prices $300 Million of Convertible Senior Notes
06.08.15
Ironwood Pharmaceuticals Announces Proposed Offering of $300 Million of Convertible Senior Notes
06.04.15
Ironwood Pharmaceuticals to Present at Goldman Sachs 36th Annual Global Healthcare Conference
05.13.15
Ironwood Presents Gastrointestinal Disease Research at Digestive Disease Week® 2015
05.07.15
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference
05.05.15
Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update
04.16.15
Ironwood Pharmaceuticals Appoints Lawrence Olanoff, M.D., Ph.D., to Board of Directors
04.15.15
Ironwood Pharmaceuticals to Host First Quarter 2015 Investor Update Call
03.09.15
Exact Sciences and Ironwood Pharmaceuticals Enter Co-Promotion Agreement for Cologuard®
03.05.15
Ironwood Pharmaceuticals Initiates Phase I Clinical Study of sGC Stimulator IW-1973
03.04.15
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference
02.23.15
Ironwood Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference
02.12.15
Ironwood Pharmaceuticals Provides Fourth Quarter 2014 Investor Update
02.04.15
Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease
01.29.15
Ironwood Pharmaceuticals to Host Fourth Quarter 2014 Investor Update Call
01.05.15
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Media contact
Meredith Kaya
617.374.5082
mkaya@ironwoodpharma.com

Latest Tweets